SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.5976
-0.0787 (-11.64%)
At close: Nov 2, 2026, 4:00 PM EST
0.6100
+0.0124 (2.07%)
Pre-market: Nov 3, 2026, 4:01 AM EST
SciSparc Employees
SciSparc had 3 employees as of December 31, 2025. The number of employees increased by 1 or 50.00% compared to the previous year. That makes SciSparc the 43,008th largest employer in the world and 6,999th in the United States.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
$226,333
Profits / Employee
-$2,740,667
Market Cap
347.19K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 1 | 50.00% |
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 0 | - |
| Dec 31, 2021 | 3 | 1 | 50.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Jaguar Health | 47 |
| Scinai Immunotherapeutics | 45 |
| Virax Biolabs Group | 26 |
| Silexion Therapeutics | 14 |
| Biodexa Pharmaceuticals | 11 |
| Decoy Therapeutics | 11 |
| Artelo Biosciences | 7 |
SPRC News
- 11 days ago - SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome - GlobeNewsWire
- 14 days ago - SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications - GlobeNewsWire
- 18 days ago - SciSparc shifts focus toward Agentic AI-powered technologies - TheFly
- 18 days ago - SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies - GlobeNewsWire
- 26 days ago - SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture - GlobeNewsWire
- 5 weeks ago - SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine - TheFly
- 5 weeks ago - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - GlobeNewsWire
- 2 months ago - SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire